Rib-X Pharmaceuticals (New Haven, CT), a clinical-stage pharmaceutical company developing next-generation antibiotics, closed an $18.7M Series B financing. Participants include Vatera Healthcare Partners, Warburg Pincus, ABS Ventures and Vox Equity Partners.